系统性硬化症患者自体干细胞移植采用减低环磷酰胺剂量的动员方案可行
该单中心回顾性研究分析32例接受自体干细胞移植的系统性硬化症患者,比较低剂量(2×1-1.5 g/m2)与高剂量(2×2 g/m2)环磷酰胺动员方案。高剂量方案在干细胞采集方面未见获益,CD34+富集后干细胞产量无显著差异(6.2 vs 5.2×106/kg体重)。低体重、低BMI(P<0.001)、既往利妥昔单抗治疗(P<0.05)和心脏受累(P<0.01)可能独立于方案选择对干细胞采集产生负面影响。
要点
- 高剂量环磷酰胺动员在干细胞采集方面未见优于低剂量方案。
- 低体重、低BMI、既往利妥昔单抗治疗和心脏受累可能与干细胞采集困难相关。
- 减低环磷酰胺动员方案在此队列中似乎可行。
核心结论
- 减低环磷酰胺动员方案似乎可行。
- 动员不良的危险因素可能为低体重、既往利妥昔单抗治疗和心脏受累。
研究设计与样本
- 单中心回顾性研究,纳入32例接受自体干细胞移植的系统性硬化症患者。
- 比较低剂量(2×1-1.5 g/m2)与高剂量(2×2 g/m2)环磷酰胺动员方案。
- 主要终点为不同环磷酰胺剂量下动员不良的发生情况。
- 次要终点为分析该系统性硬化症队列中干细胞动员困难的潜在危险因素。
主要发现
- 高剂量与减低剂量环磷酰胺组CD34+富集后干细胞产量无显著差异(6.2 vs 5.2×106/kg体重)。
- 高剂量环磷酰胺可能与更多副作用相关,但该差异未达统计学显著。
- 低体重和低BMI(P<0.001)、既往利妥昔单抗治疗(P<0.05)及心脏受累(P<0.01)可能独立于所选方案对干细胞采集产生负面影响。
关键数值与推荐
- 动员不良定义为CD34+祖细胞计数<2×106/kg体重、需增加G-CSF剂量、需使用普乐沙福或连续>2天白细胞分离术。
- 低剂量环磷酰胺方案为2×1-1.5 g/m2,高剂量方案为2×2 g/m2。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the feasibility of reduced cyclophosphamide dosing in the setting of mobilization chemotherapy prior to high dose chemotherapy and autologous stem cell transplantation in patients with SSc. The primary end point was the occurrence of 'poor mobilization' when using different cyclophosphamide dosing. The second end point was to analyse potential risk factors for difficult stem cell mobilization in this cohort of patients with SSc. METHODS: This single-centre study retrospectively reviewed 32 patients with SSc who underwent autologous stem cell transplantation. We analysed the occurrence of 'poor mobilization' (defined as CD34+ progenitor cell count <2 × 106/kg body weight, the use of increasing G-CSF dose, the use of plerixafor, or leukapheresis on >2 consecutive days) in different cyclophosphamide mobilization regimens: We herein compared low dose (2 × 1-1.5 g/m2) cyclophosphamide vs high dose (2 × 2 g/m2) for mobilization. RESULTS: Higher dosing of cyclophosphamide seems not to be beneficial regarding stem cell collection as there was no significant difference in stem cell yield between high dose and reduced dose cyclophosphamide (6.2 vs 5.2 × 106/kg bodyweight after CD34+ enrichment). Furthermore, higher doses of cyclophosphamide might be associated with more side effects; this difference was, however, not statistically significant. Lower bodyweight and BMI (P < 0.001) as well as rituximab pre-therapy (P < 0.05) and cardiac involvement (P < 0.01) might negatively impact stem cell collection independently from the chosen regimen. CONCLUSION: Our data demonstrate that a reduced cyclophosphamide mobilization regimen seems to be feasible. Risk factors for poor mobilization might be low bodyweight, prior rituximab therapy and cardiac involvement.
引用
- Pecher AC, Ach KR, Vogel W, et al. Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis. Rheumatology (Oxford). 2023. PMID: 35951758. doi:10.1093/rheumatology/keac455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。